Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
Heavy losses for Pacira Pharmaceuticals today as the stock fell by -€0.800 (-4.040%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Pacira Pharmaceuticals.
With a target price of 29 € there is a hugely positive potential of 52.63% for Pacira Pharmaceuticals compared to the current price of 19.0 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -4.040% | -2.538% | 10.983% | -23.810% | -11.111% | -50.259% | -68.264% |
| Twist Bioscience Corp | 2.280% | -5.873% | 17.356% | 6.439% | 50.772% | 131.121% | -63.487% |
| Rockwell Medical Inc. | -1.650% | -10.203% | -15.170% | -50.857% | 14.486% | -61.275% | -93.824% |
| Vericel Corp. | -0.630% | -5.590% | -4.403% | -39.200% | -3.797% | 5.997% | -24.171% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat